Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

ClinicalTrials.gov ID: NCT07165132

Public ClinicalTrials.gov record NCT07165132. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1 First-in-Human, Dose Escalation and Dose Expansion Study of RYZ401, a Novel Radiopharmaceutical Therapy Labeled With Actinium-225, in Subjects With Neuroendocrine Tumors and Other Solid Tumors Expressing Somatostatin Receptors.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.

Study identification

NCT ID: NCT07165132
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: RayzeBio, Inc.; Industry
Enrollment: 104 participants

Conditions and interventions

Conditions

Interventions

RYZ401 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 3, 2025 (Actual)
Primary completion: Feb 2027 (Estimated)
Completion: Apr 2033 (Estimated)
Last update posted: Sep 15, 2026

2025 – 2033

United States locations

U.S. sites: 12
U.S. states: 11
U.S. cities: 11

Facility	City	State	ZIP	Site status
Research Facility	Phoenix	Arizona	85054	Recruiting
Research Facility	Jacksonville	Florida	32224	Recruiting
Research Facility	Iowa City	Iowa	52242	Recruiting
Research Facility	Lexington	Kentucky	40536	Recruiting
Research Facility	Rochester	Minnesota	55905	Recruiting
Research Facility	St Louis	Missouri	63104	Recruiting
Research Facility	St Louis	Missouri	63110	Recruiting
Research Facility	Columbus	Ohio	43210	Recruiting
Research Facility	Portland	Oregon	97239	Recruiting
Research Facility	Nashville	Tennessee	37232	Recruiting
Research Facility	Salt Lake City	Utah	84112	Recruiting
Research Facility	Charlottesville	Virginia	22903	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07165132, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 15, 2026 · Synced Oct 22, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07165132 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →